Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
about
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cellsTherapeutic cancer vaccines: past, present, and futureEvaluation of current cancer immunotherapy: hemato-oncologyMonitoring of the Immune Dysfunction in Cancer PatientsImmunosuppressive strategies that are mediated by tumor cellsTargeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growIntratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell response.Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumorsMyeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.Immune response in thyroid cancer: widening the boundaries.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo.T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapyTumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.Tregs and rethinking cancer immunotherapy.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeBlockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cellsCancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulationImmunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.Immunosuppressive tumor microenvironment in cervical cancer patientsB7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunityRegulatory considerations for clinical development of cancer vaccinesAssociation of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention.Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
P2860
Q24681974-E4FBEFFF-7787-4471-A107-C828E157DC04Q26863283-513EC4B9-3B38-4E85-BDBF-12EC1352E3E9Q27006179-509E4209-A3E1-4A72-944F-4B83EFAA3C44Q28072712-E1B49414-21AD-4184-9BAB-D9F4B1157783Q29636247-A31A8DF7-C652-4360-93D4-C2D38E7BE6C5Q33584637-5590B09A-9A71-4B68-907B-C26084ABD2EAQ33598811-3B146910-45EE-4818-B907-33D6B46DF89FQ33737660-C408A6BD-832D-48CA-AD22-40A3A4AA65A8Q33754618-8DE24FF9-D08C-4148-9247-0DC8B4A00375Q33754742-F533CB12-F046-4744-9006-A3C2D863DDC6Q33772507-951AA6D6-E25E-425A-83B9-4A2B1C1DEFCEQ33824623-11E7814C-0E0C-404F-8B69-BFF5ED7F7243Q33919954-A5840397-8F5B-4DFD-AB47-0A90577C5FB8Q33977826-3C916459-E1B8-460A-9E90-63D634A54FCCQ34097414-07C03670-8A1B-4364-967A-3BD227621C4CQ34310495-629BD091-782B-4B74-9255-B95CB0FACD05Q34418112-2B1192A4-8C7F-4BBD-B718-D58D6E5A8577Q34427407-A1E46D8C-1674-4699-B374-EF470D30CCCCQ34475726-CF919BB4-2208-48E5-8ECD-1B1703D3E191Q34534544-2C47BD04-8C30-4E68-8C28-892A7D1D067DQ34542545-072B12C9-ED9F-4E97-8E1D-61EEFC822EACQ34610483-74CB5812-7A1F-4EBB-9F1D-97FA2DFD0547Q34625147-B99E0C22-F1CF-4F78-9750-1AC0D1A3E049Q34645401-4488FF90-411F-40BF-B7A5-9A37D664E9F4Q34801069-7172CD7C-5242-48A0-BC78-E0AAB87A9DBEQ34856691-57123CE8-6418-466A-AB0F-8146ECBFB293Q34983123-3F2363C2-AE89-43E6-9C4F-349B39494FE5Q35020804-CA8B1F6C-D5ED-4CF0-9106-3A31AD25919DQ35033249-79861672-E462-4EAD-8C60-3BBA546AB1DEQ35049821-2C0E0DA6-C185-407E-94D6-08A1D3181C87Q35269390-4B97DF39-4055-4F1F-BAE7-7296738A9053Q35552042-C722859B-BC0E-446C-8AC7-4158D5FB643EQ35603131-22A032E7-71CE-4B24-A3D5-4DC4E166B70CQ35813519-C23B1191-D81D-4189-ACF3-06D87FE5C0C1Q35848586-3A85DA36-42CD-4C9D-9BA7-CBA800413974Q35886454-34A02A9A-2D5F-4683-8A1A-E1AC30B93181Q35901282-95FB6113-A006-4A57-8F06-95A90354FA8DQ36057441-5C0D7BB2-C8A3-4A82-B0BC-879CDBAFF7D2Q36398745-A3EE707A-F7BA-45FE-986A-1177DD6B2BFDQ36445855-23C6348D-2811-4FBC-A844-C1B5618027F0
P2860
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@ast
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@en
type
label
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@ast
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@en
prefLabel
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@ast
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@en
P2093
P2860
P1433
P1476
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
@en
P2093
Charles G Drake
Hyam I Levitsky
P2860
P304
P356
10.1182/BLOOD-2005-07-2737
P407
P577
2005-09-22T00:00:00Z